Biotech Values

[biomaven0]

>>meets primary endpoint in phase-3b migraine study

Well oral sumatriptan is fairly slow-acting, so they were pretty much going up against a placebo in their 30 minute endpoint.

The standard FDA endpoint is pain relief at 2 hours. They didn't disclose those numbers, although likely they would have been OK.

Oral sumatriptan is clearly (but not dramatically) inferior to the 2nd-generation triptans in effectiveness and side-effect profile. A good example of how sometimes first-in-class in this type of indication keeps a good market share although inferior to best-in-class.

Peter